- Home
- CHYM vs UTHR Comparison
CHYM vs UTHR Comparison
Compare CHYM & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHYM
- UTHR
- Stock Information
- Founded
- CHYM 2012
- UTHR 1996
- Country
- CHYM United States
- UTHR United States
- Employees
- CHYM N/A
- UTHR N/A
- Industry
- CHYM Finance: Consumer Services
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- CHYM Finance
- UTHR Health Care
- Exchange
- CHYM Nasdaq
- UTHR Nasdaq
- Market Cap
- CHYM 13.5B
- UTHR 14.4B
- IPO Year
- CHYM 2025
- UTHR 1999
- Fundamental
- Price
- CHYM $29.91
- UTHR $289.79
- Analyst Decision
- CHYM
- UTHR Buy
- Analyst Count
- CHYM 0
- UTHR 13
- Target Price
- CHYM N/A
- UTHR $393.08
- AVG Volume (30 Days)
- CHYM 12.3M
- UTHR 690.9K
- Earning Date
- CHYM 01-01-0001
- UTHR 07-30-2025
- Dividend Yield
- CHYM N/A
- UTHR N/A
- EPS Growth
- CHYM N/A
- UTHR 18.86
- EPS
- CHYM N/A
- UTHR 25.10
- Revenue
- CHYM $1,800,041,000.00
- UTHR $2,994,100,000.00
- Revenue This Year
- CHYM N/A
- UTHR $14.30
- Revenue Next Year
- CHYM N/A
- UTHR $6.32
- P/E Ratio
- CHYM N/A
- UTHR $11.62
- Revenue Growth
- CHYM 30.88
- UTHR 19.84
- 52 Week Low
- CHYM $31.21
- UTHR $266.98
- 52 Week High
- CHYM $44.94
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- CHYM N/A
- UTHR 42.06
- Support Level
- CHYM N/A
- UTHR $282.89
- Resistance Level
- CHYM N/A
- UTHR $329.85
- Average True Range (ATR)
- CHYM 0.00
- UTHR 9.04
- MACD
- CHYM 0.00
- UTHR -2.91
- Stochastic Oscillator
- CHYM 0.00
- UTHR 25.12
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.